Investor Presentaiton
Novo Nordisk Annual Report 2023
OBESITY
Introducing Novo Nordisk Strategic Aspirations Risks
Management
Consolidated statements
Additional information
Controlled launches for
market-leading obesity therapy
GLOBAL PREVALENCE OF OBESITY IN ADULTS (millions)
- Obesity
2,000
Surging demand, limited supply and unprecedented global
media attention on our ground-breaking obesity treatment,
WegovyⓇ, have brought significant challenges - as well as
exciting long-term opportunities.
Demand for WegovyⓇ is still growing strongly in the US, its first
launch market, and we have taken proactive steps to conduct
controlled and limited roll-outs in other major markets, with the
goal of reaching the patients in greatest need of the therapy
despite ongoing supply constraints.
"Novo Nordisk is also reserving a share of
Wegovy supply in each new launch
market for patients who cannot afford to
pay for the product out of pocket."
In the UK, for example, WegovyⓇ is now available in specialist
National Health Service weight management services for people
who meet strict criteria, or else privately through a registered
healthcare professional. UK physicians are being urged to
prescribe responsibly and Novo Nordisk is also reserving a share
of WegovyⓇ supply in each new launch market for patients who
cannot afford to pay for the product out of pocket.
The success of WegovyⓇ, which builds on our experience with
our first-generation GLP-1-based obesity product SaxendaⓇ,
means that Novo Nordisk has captured most of the growth and
gained a clear leadership position in the obesity market. The
sector remains extremely dynamic, with new players lining up to
enter the space amid a growing appreciation that medicines
tackling obesity have the potential to boost public health and
cut long-term healthcare costs.
Globally, the number of people living with obesity has almost
tripled since 1975 and is set to reach over 1.2 billion adults by
2030. The causes of obesity are complex and its consequences
far-reaching because, so often, it puts people on a path to other
diseases - not only diabetes, but also heart and liver diseases,
cancers and many more.
Today, only one in 10 people living with obesity seek
professional medical help - and only one in five of those receive
treatment with a weight management medication. But attitudes
are changing fast. The past two years have been characterised
by a growing understanding among both the medical
community and the public of the critical need to treat obesity,
while an increasing number of people living with the disease are
actively seeking support. We want to understand more about
their journey and how we can continue to help them maintain
their long-term progress towards better health.
1,600
1,532
1,246
1,200
1,007
813
800
400
0
2020
2025
2030
2035
Source: Obesity Atlas, 2023.
OBESITY SALES (DKK billion)
‣ Sales as reported Growth at CER
50
40
30
20
55%
3%
10
84%
154%)
0
2020
2021
2022
2023
32View entire presentation